Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Anticonvulsant

or Neuroleptic

or [[:Category:Neuropathic pain medicines|Neuropathic pain medicine]]

Use the filters below to narrow your results.

Amitriptyline (hydrochloride) (1) · Asenapine (1) · Brivaracetam (1) · Cannabidiol (1) · Cenobamate (1) · Chlorpromazine (1) · Clobazam (1) · Droperidol (1) · Eslicarbazepine (1) · Ethosuximide (1) · Felbamate (1) · Fenfluramine (1) · Fluphenazine (1) · Fosphenytoin (1) · Gabapentin (1) · Iloperidone (1) · Lacosamide (1) · Loxapine (1) · Lurasidone (1) · Molindone (1) · Nortriptyline (hydrochloride) (1) · Paliperidone (1) · Perampanel (1) · Perphenazine (1) · Phenobarbital (1) · Phenytoin (1) · Pimozide (1) · Pregabalin (1) · Rufinamide (1) · Stiripentol (1) · Thioridazine (1) · Thiothixene (1) · Tiagabine (1) · Trifluoperazine (1) · Valproic acid (1) · Vigabatrin (1) · Ziprasidone (1) · Zonisamide (1)

Aptiom (1) · Banzel (1) · Briviact (1) · Cerebyx (1) · Depakote (1) · Diacomit (1) · Dilantin (1) · Elavil (US brand discontinued; generic widely available), Endep, Tryptizol (1) · Epidiolex (1) · Fanapt (1) · Felbatol (1) · Fintepla (1) · Fycompa (1) · Gabitril (1) · Geodon (1) · Inapsine (1) · Invega (1) · Latuda (1) · Loxitane (1) · Luminal (1) · Lyrica (IR), Lyrica CR (1) · Mellaril (1) · Moban (1) · Navane (1) · Neurontin (IR), Gralise (ER), Horizant (gabapentin enacarbil ER) (1) · Onfi (1) · Orap (1) · Pamelor (US brand discontinued; generic widely available), Aventyl (1) · Prolixin (1) · Sabril (1) · Saphris (1) · Stelazine (1) · Thorazine (1) · Trilafon (1) · Vimpat (1) · Xcopri (1) · Zarontin (1) · Zonegran (1)

None (3) · AMPA receptor antagonist (1) · Butyrophenone D2 antagonist (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) · GABA reuptake inhibitor (GAT-1 blocker) (1) · GABAA positive allosteric modulator (1) · GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) · GABAA potentiator and direct activator (1) · Irreversible GABA-T inhibitor (1) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) · NMDA antagonist; GABAA potentiator (1) · Phenothiazine D2 antagonist (4) · Prodrug of phenytoin; sodium channel blocker (1) · Serotonin releaser; sigma-1 agonist (1) · Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) · Sodium channel blocker (2) · Sodium channel blocker; GABAA positive allosteric modulator (1) · Sodium channel modulator (1) · Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) · SV2A ligand (higher affinity than levetiracetam) (1) · T-type calcium channel blocker (1) · Thioxanthene D2 antagonist (1) · '"`UNIQ--vote-00000019-QINU`"' Therapeutic plasma-level monitoring is standard practice for TCAs given the narrow therapeutic index and the established plasma-level-efficacy correlation. CYP2D6 substrate; CPIC PGx guidance applies for dose individualization'"`UNIQ--ref-0000001A-QINU`"'. (1)

None (34) · 300 mg PO at bedtime night 1, 300 mg BID day 2, 300 mg TID day 3; titrate to clinical effect, commonly 1800-3600 mg/day divided TID (1) · Depression (rarely used now): 25-75 mg PO at bedtime, titrate to 150 mg/day. Neuropathic pain / migraine prophylaxis: 10-25 mg at bedtime, titrate by 10-25 mg weekly to 50-100 mg/day. Elderly: 10 mg at bedtime (Beers-list cautions apply) (1) · Depression: 25 mg PO TID-QID or 75 mg at bedtime, titrate to 75-150 mg/day. Neuropathic pain: 10-25 mg at bedtime, titrate to 50-100 mg/day. Elderly: 10 mg at bedtime (Beers-list cautions, though less than amitriptyline) (1) · Neuropathic pain: 75 mg PO BID, titrate to 150 mg BID after 1 week. Fibromyalgia: 75 mg PO BID, titrate to 150 mg BID. Anxiety (off-label): 75-150 mg/day divided BID-TID (1)

None (34) · Capsules 10, 25, 50, 75 mg; oral solution 10 mg/5 mL (1) · Capsules 100, 300, 400 mg; tablets 600, 800 mg; oral solution 250 mg/5 mL; Gralise ER tablets 300, 600 mg (once-daily); Horizant ER tablets 300, 600 mg (gabapentin enacarbil, an inactive parent compound metabolized to gabapentin in vivo) (1) · Capsules 25, 50, 75, 100, 150, 200, 225, 300 mg; oral solution 20 mg/mL; Lyrica CR tablets 82.5, 165, 330 mg (1) · Tablets 10, 25, 50, 75, 100, 150 mg (1)

None (34) · 150 mg/day; therapeutic plasma-level monitoring recommended (target 50-150 ng/mL window) (1) · 300 mg/day (historical hospitalized inpatient depression); 150 mg/day outpatient typical ceiling (1) · 3600 mg/day; off-label doses higher are common but bioavailability saturates well below this (1) · 600 mg/day (seizures); 450 mg/day (fibromyalgia and neuropathic pain) (1)

None (34) · Oral (4)

None (34) · 1-2 weeks for neuropathic pain and anxiolytic effect; anticonvulsant effect at therapeutic plasma level (1) · Neuropathic pain and fibromyalgia effect emerges over 1-2 weeks (1) · Pain and migraine prophylaxis effect 1-4 weeks; antidepressant effect 4-6 weeks (1) · Sleep effect from first dose; analgesic and migraine-prophylaxis effect 1-4 weeks; antidepressant effect 4-6 weeks (1)

None (34) · 24 hours (HS dosing) (2) · BID-TID dosing for IR; once-daily for CR (1) · TID dosing for IR; once-daily for ER formulations (1)

None (34) · 18-44 hours'"`UNIQ--ref-00000020-QINU`"' (1) · 5-7 hours'"`UNIQ--ref-00000029-QINU`"' (1) · 6.3 hours'"`UNIQ--ref-00000026-QINU`"' (1) · Amitriptyline 10-50 hours (highly variable); nortriptyline active metabolite 18-44 hours'"`UNIQ--ref-00000026-QINU`"' (1)

None (34) · '''Saturable''' via the LAT-1 amino-acid transporter, producing nonlinear pharmacokinetics: ~60% at 300 mg single dose, falling to ~35% at 1200 mg single dose'"`UNIQ--ref-0000002A-QINU`"' (1) · ~50% (oral)'"`UNIQ--ref-00000021-QINU`"' (1) · ~50% (oral)'"`UNIQ--ref-00000027-QINU`"' (1) · ≥90% (linear pharmacokinetics, distinguishing it favorably from gabapentin's saturable LAT-1 absorption)'"`UNIQ--ref-00000027-QINU`"' (1)

None (34) · Limited human data; some signal for cardiac malformations and developmental delay but confounded by maternal disease and polytherapy.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Older agent with substantial use experience; observational signals not clearly causal.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Some signal for major congenital malformations; limited human data.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · TCA class signal; limited human data specific to nortriptyline.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

None (35) · '''[[USLegal:Schedule V|Schedule V controlled substance]] in US (federally)''', distinct from gabapentin which remains federally unscheduled'"`UNIQ--ref-00000028-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-00000022-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-00000028-QINU`"' (1)